Excellergy

📍 Palo Alto, United States👥 11 employees💰 Last funded Jan 2021
Biotechnology Research🌐 excellergy.com
Website LinkedIn
Excellergy is a biotechnology company developing a first-in-class portfolio of trifunctional effector cell response inhibitors (ECRIs) to combat severe allergic diseases and help improve patient quality of life. By leveraging clinically validated Immunoglobulin E (IgE) biology with novel ECRI pharmacology, Excellergy is advancing beyond traditional anti-IgE approaches to directly target the source of allergic signaling—IgE bound to the effector cell. The company was founded by leaders in the field of IgE biology and the molecular pharmacology of anti-IgE therapeutics.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Excellergy?
Excellergy has 1 investors on record on gritt.io.
When did Excellergy last raise funding?
The most recent investment in Excellergy recorded on gritt.io was in January 2021.
What industry is Excellergy in?
Excellergy operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Excellergy based?
Excellergy is headquartered in Palo Alto, United States.